MedPath

Ulixertinib

Generic Name
Ulixertinib
Drug Type
Small Molecule
Chemical Formula
C21H22Cl2N4O2
CAS Number
869886-67-9
Unique Ingredient Identifier
16ZDH50O1U
Background

Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity . It is currently in clinical trials for the treatment of a wide range of tumors.

Clinical Trials
Related News

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Phase 1
Recruiting
Conditions
Tumor, Solid
Pancreatic Cancer
Melanoma
Interventions
First Posted Date
2018-03-05
Last Posted Date
2025-03-18
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
45
Registration Number
NCT03454035
Locations
🇺🇸

Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

Phase 2
Active, not recruiting
Conditions
Uveal Melanoma
Interventions
First Posted Date
2018-01-31
Last Posted Date
2024-06-25
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
13
Registration Number
NCT03417739
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Phase 2
Active, not recruiting
Conditions
Advanced Malignant Solid Neoplasm
Juvenile Xanthogranuloma
Langerhans Cell Histiocytosis
Malignant Glioma
Recurrent Childhood Rhabdomyosarcoma
Recurrent Ewing Sarcoma
Recurrent Osteosarcoma
Recurrent Primary Central Nervous System Neoplasm
Refractory Hepatoblastoma
Refractory Medulloblastoma
Interventions
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Other: Laboratory Biomarker Analysis
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Mutation Carrier Screening
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Other: Pharmacological Study
Procedure: Radionuclide Imaging
Procedure: Positron Emission Tomography
Procedure: X-Ray Imaging
First Posted Date
2017-05-16
Last Posted Date
2025-05-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
1376
Registration Number
NCT03155620
Locations
🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Providence Alaska Medical Center, Anchorage, Alaska, United States

🇺🇸

Banner Children's at Desert, Mesa, Arizona, United States

and more 169 locations

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

Phase 1
Terminated
Conditions
Pancreatic Cancer
Cancer of Pancreas
Cancer of the Pancreas
Pancreas Cancer
Interventions
Procedure: Tumor biopsy
First Posted Date
2015-11-18
Last Posted Date
2021-04-21
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
18
Registration Number
NCT02608229
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2
Active, not recruiting
Conditions
Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Bladder Carcinoma
Breast Carcinoma
Cervical Carcinoma
Colon Carcinoma
Colorectal Carcinoma
Endometrial Carcinoma
Esophageal Carcinoma
Exocrine Pancreas Carcinoma
Interventions
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Cytology Specimen Collection Procedure
Procedure: Radiologic Examination
Procedure: Multigated Acquisition Scan
Procedure: Echocardiography Test
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Procedure: Radionuclide Imaging
First Posted Date
2015-06-08
Last Posted Date
2025-05-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
6452
Registration Number
NCT02465060
Locations
🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

🇺🇸

Thomas Hospital, Fairhope, Alabama, United States

🇺🇸

Mobile Infirmary Medical Center, Mobile, Alabama, United States

and more 1406 locations

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

Phase 1
Completed
Conditions
Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Interventions
First Posted Date
2014-11-20
Last Posted Date
2019-01-29
Lead Sponsor
BioMed Valley Discoveries, Inc
Target Recruit Count
53
Registration Number
NCT02296242
Locations
🇺🇸

Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

UCLA Medical Center, Los Angeles, California, United States

and more 2 locations

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2013-02-01
Last Posted Date
2020-03-20
Lead Sponsor
BioMed Valley Discoveries, Inc
Target Recruit Count
136
Registration Number
NCT01781429
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 6 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy